Key Points {#FPar1}
==========

This research identified the ten most relevant attributes within three domains that can influence patients' decisions when making treatment choices for inflammatory bowel diseases (IBD).The descriptive framework could be used to facilitate discussion between patients and physicians when reviewing IBD treatment options.Additional research to quantify the importance of each attribute in patient preferences is needed.

Introduction {#Sec1}
============

Crohn's disease (CD) and ulcerative colitis (UC) are chronic, systemic inflammatory bowel diseases (IBD) with significant potential burden and resulting disability for patients \[[@CR1], [@CR2]\]. The incidence and prevalence of UC and CD vary within different geographic locations. The most prevalent regions include North America, Northern Europe, and Australia, but prevalence is increasing in regions where this has historically been low, such as Africa, South America, and Asia \[[@CR3], [@CR4]\].

Patients experience IBD differently based on the severity of the disease, the coexistence of other autoimmune diseases or extra-intestinal manifestations; and treatment for these conditions varies according to diverse patterns of clinical practice \[[@CR5], [@CR6]\]. Medications used for the treatment of IBD include aminosalicylates, glucocorticoids, immunomodulators, biologics, and small molecules, with each class having distinct characteristics that will influence patient choice. Patient and physician preferences for IBD treatment options may also differ, thus communication between patients and physicians is crucial in the shared decision-making process \[[@CR7]\].

Qualitative patient preference data identify which outcomes, endpoints, or treatment attributes are relevant to patients, whereas quantitative patient preference data estimate how much the different attributes matter to patients and the trade-offs that patients are willing to make \[[@CR8]\]. Although the qualitative approach required to develop descriptive frameworks to describe treatment alternatives has been thoroughly described \[[@CR9]\], there is limited information on which qualitative data or methods should be used to conduct a quantitative study on patient preferences. In the past, descriptive frameworks for health preference research were developed based on literature, non-preference-based health surveys, or expert opinion (top-down methods) \[[@CR10]\]. More recently, the bottom-up methodology has been prevailing over the top-down methods. In this approach, patients are considered central to the process and their experiences and opinions on how the disease affects their lives are incorporated into the methodology \[[@CR8]\].

Without a clear understanding of the patient perspective, the results of preference studies can be inconclusive or misleading. Although there is no consensus on which qualitative methods should be applied after a literature review, there is agreement that literature searches alone are insufficient to adequately develop a descriptive framework for a robust preferences study \[[@CR9]\]. The use of focus groups, in-depth interviews, and Delphi panels can be useful and provide a stronger methodology for qualitative research \[[@CR11], [@CR12]\].

To date, there is limited research that evaluates how different treatment characteristics may affect treatment choice for IBD patients, particularly with respect to the increasing range of mechanisms of action of new agents that will be entering the IBD space in the next few years. Moreover, the published literature on patients' values/preferences for IBD treatment presents highly variable results \[[@CR13]--[@CR17]\].

The objective of the study presented here was to create a descriptive framework that includes the most relevant attributes that influence patients' decision making regarding IBD treatment. The current research should serve as a solid foundation for future preference elicitation studies analysing the utility values of the attributes.

Methods {#Sec2}
=======

A literature review, a focus group meeting, and structured online voting were conducted to identify the most relevant attributes associated with treatment decision making in IBD.

Literature Review {#Sec3}
-----------------

A literature review was performed on published health preference studies to identify preferences or attitudes towards pharmacological treatment in adult patients suffering from mild to severe IBD conditions. To inform and facilitate the literature search, we used the Population/Problem, Intervention, Comparison, Outcome, Study type (PICOS) framework. Both general and highly specialized international databases and registries (PubMed, Cochrane Library, International Society for Pharmacoeconomics and Outcomes Research, ClinicalTrials.gov, and the Health Preference Study and Technology Registry of the International Academy of Health Preference Research---<https://hpstr.org/landing>) were searched from January 1, 2000 to June 19, 2018, using the medical subject heading (MeSH) terms "preference", "attitude to health", "willingness to pay", "time trade-off", "standard gamble", "conjoint", "discrete choice", "best--worst", "utility", "inflammatory bowel disease", "Crohn disease", and "ulcerative colitis" {e.g. ((((((inflammatory bowel disease\[Title/Abstract\] OR Crohn Disease\[Title/Abstract\] OR ulcerative colitis)\[Title/Abstract\] AND ((preference\[Title/Abstract\] OR attitude to health\[Title/Abstract\] OR willingness to pay\[Title/Abstract\] OR time trade-off\[Title/Abstract\] OR discrete choice\[Title/Abstract\] OR conjoint\[Title/Abstract\] OR utility\[Title/Abstract\])) AND ("2000/01/01"\[Date - Publication\]: "2018/06/19"\[Date - Publication\])) AND (therapy)) NOT osteopathy) NOT surgery}. Preference research of both qualitative and quantitative research as well as articles on input from patients and clinical experts were included. Publications related to surgery and alternative medical options were excluded.

Two reviewers independently screened the titles of the resulting citations for eligibility, and articles that were out of scope, duplicates, based on animal models, or studies in paediatric populations were discarded. Out of scope articles included publications focused on general satisfaction with health care provision, probiotics, preferences about being involved in shared decision making decisions, or satisfaction in the transition from paediatric to adulthood management of IBD. Publications that aimed to explore factors associated with health service utilization and preference for services, aimed to assess the appropriateness of immunosuppressive therapy in different scenarios, preferences on exercise, studies in pregnant women to evaluate their adherence, general reviews on adherence and preferences for psychological interventions, general overview/reviews, opinion letters, overview of quality improvement initiatives in IBD, state or art of treatments and management, preferences for diagnostic procedures were also considered out of scope.

Following the title screening step, the abstracts of the remaining articles were reviewed using the same criteria. The reviewers then independently screened the full text of the remaining articles following the abstract screening using the same criteria as the first two steps. Reviewers adjudicated conflicts through discussion or consultation with a third reviewer. After the title, abstract, and full-text screening steps, the reviewers identified and classified the relevant attributes across different domains (e.g. effectiveness, side effects, health-related quality of life \[HRQoL\], and well-being). Generic attributes, such as reduction of side effects, were not considered in this research. Although the same attributes were defined for UC and CD, the relative importance of each attribute to UC or CD was considered.

Focus Group Meeting {#Sec4}
-------------------

We aimed to conduct a focus group of approximately 16--18 participants to determine patients' values and opinions regarding different treatment attributes. To have different perspectives, an invitation letter to participate in the research was sent to patient associations and gastroenterologists from several countries. We aimed to recruit one patient representative per gastroenterologist. Those who expressed an interest in participating were contacted directly by the research team, and, at that point, the research project was explained in more detail. A written agreement was obtained if they were aged 18 years or older, were able to speak English, and could travel to the focus group meeting venue to participate.

The focus group meeting was conducted on September 28, 2018 in Frankfurt, Germany. To determine the most relevant treatment attributes while considering both patient and physician perspectives, eight patient representatives and nine gastroenterologists were included. Patients represented local patient associations or local groups from countries such as Belgium, Canada, Spain, Germany, the UK, and Israel. The gastroenterologists were IBD specialists from academic medical centres with special interest and/or expertise in patient preferences, quality of life, and patient-reported outcomes, and represented the same countries as the patients. In addition to providing their perspective on the attributes, the gastroenterologists also provided clinical expertise.

Information on the objectives, methodology, and results from the literature review was shared with all participants prior to the meeting and was further reviewed with the focus group participants during the focus group meeting. Additionally, the results of the literature review and an explanation of the identified domains and attributes were provided. Through discussion, the focus group participants aligned on which attributes should be included in each domain. All participants had the chance to state their opinions regarding the importance of each different treatment attribute.

Although the focus group meeting was not recorded, a transcript of the discussions was developed by a stenographer. Using the transcript, a tally was developed to indicate the number of participants who considered each attribute meaningful. These responses informed the subsequent draft of the descriptive framework that included the attributes grouped into domain subsets.

Structured Rounds of Voting {#Sec5}
---------------------------

Following the focus group, the eight patient representatives and nine gastroenterologists participated in two rounds of online voting with the objective of refining the specific wording of the descriptive framework. The structured rounds of voting were designed to minimize the potential bias introduced by the research team or dominant participants in the focus group meeting by providing patients with the opportunity to individually review the information and to contribute feedback without the influence of other participants/colleagues.

The simplified list of attributes included in the descriptive framework was shared during the first round of voting. For each attribute, a question provided suggested wording for that attribute and asked whether the participant agreed or not; participants also had the opportunity to suggest additional changes to the wording. Additionally, participants were asked to rank all the attributes included in the descriptive framework from most to least relevant (global ranking task). All responses from the wording questions and global ranking task were analysed using qualitative methods for free-text comments and frequencies for response options. The free-text comments were analysed to identify valuable context to better understand the responses or to improve the wording of the attributes. Based on the first round of voting, a refined version of the descriptive framework was developed.

The second round of voting aimed to determine which attributes could potentially be removed from the final descriptive framework. This method was used to minimize the final number of attributes to be similar to the maximum number of attributes that are currently tested in patient preference studies. The average number of attributes reported in the literature is six, with a minimum value of two and a maximum value of 12 \[[@CR18]\]. While more consideration was given to the patients' responses, the gastroenterologists' responses were considered when there was not a clear consensus among the patient responses. The total number of attributes included in the final list was based on the importance of each individual attribute provided by the patient participants as well as the experience of the research team in creating a valuable descriptive framework.

Results {#Sec6}
=======

Literature Review {#Sec7}
-----------------

The question statements used to inform the PICOS framework are presented in Online Resource Table S1 (see the electronic supplementary material \[ESM\]). The literature search identified 574 records. The titles of these citations were screened for their relevance to the research topic, resulting in 109 articles to be further assessed for eligibility by abstract screening. The abstract screening step eliminated 72 additional records. The full text of the remaining 37 publications was evaluated based on pre-specified eligibility criteria, and 32 publications on patient preferences were included in this research (Fig. [1](#Fig1){ref-type="fig"}). The most common reasons for excluding publications were out of scope (473), duplicates (20), and studies in the paediatric population (19).Fig. 1Literature flow diagram. \*Used as a complementary source to confirm that all the relevant endpoints in clinical investigation had been identified. *ISPOR* International Society for Pharmacoeconomics and Outcomes Research, *NIH* National Institutes of Health

A total of 127 attributes were identified based on the 32 publications (Online Resource Table S2; see the ESM). These attributes were grouped into seven different domains (effectiveness, side-effects, HRQoL, well-being, available evidence, administration/convenience, and other).

Focus Group Meeting {#Sec8}
-------------------

Although not identified in the selected publications, skin cancer and herpes zoster are side effects in the treatment of IBD and a matter of concern for patients and physicians \[[@CR19], [@CR20]\]. Based on the focus group discussion, these attributes were added to the list.

Table [1](#Tab1){ref-type="table"} shows the draft of the descriptive framework that was developed based on the feedback received during the focus group meeting. The draft included 16 relevant attributes within five different domains (efficacy, complications/risk, HRQoL/well-being, administration, and cost/co-payment). Pain, stool control (specifically defined by bowel urgency), rectal bleeding, endoscopic results, fatigue/loss of energy, and rapidity of action of treatment were the most valued efficacy attributes based on the focus group meeting. Among the complication and risk attributes, the participants selected the risk of life-threatening cancer and serious infections within the next 10 years, risk of mild to moderate complications, aesthetic complications related to treatment, and the need to remain on steroids as being the most relevant. HRQoL and well-being attributes, such as emotional status, sexual life, social life and relationships, and functional performance in daily activities, as well as treatment administration (mode, frequency, and place of administration) and cost of treatment in general were also valued by the participants in the focus group meeting.Table 1Shortened list of attributes grouped in redefined domains agreed on in the focus group meeting and patients' ranking from the first round of votingDomainAttribute nameRankEfficacyPain2Stool control1Rectal bleeding14Endoscopic results13Fatigue/loss of energy3Rapidity of action of treatment10Complications/riskRisk of life-threatening cancer and serious infections within the next 10 years6Risk of mild to moderate complications9Aesthetic complications related to treatment8Need to remain on steroids12HRQoL/well-beingEmotional status5Sexual life11Social life and relationships7Functional performance in daily activities4AdministrationTreatment administration15Cost/co-paymentCost16*HRQoL* health-related quality of life

Structured Voting Rounds {#Sec9}
------------------------

A refined version of the descriptive framework was developed after the first round of voting. The full survey used in the first round of voting is available in the ESM. The number of attributes included in the structured voting was based on the global ranking task included in the first round of voting (Table [1](#Tab1){ref-type="table"}). Stool control, pain, and fatigue/loss of energy were considered more important than endoscopic results, rectal bleeding, treatment administration, and cost according to patient participants. The attributes that received lower ranking were removed from the attribute list. Following the first round of structured voting, the descriptive framework included 14 attributes within three different domains (efficacy, complications/risk, and HRQoL/well-being).

During the second round of voting, participants expressed which attributes they would most likely remove from the final draft of the descriptive framework (Fig. [2](#Fig2){ref-type="fig"}). Stool frequency, rapidity of treatment action, and functional performance in daily activities were the most common attributes recommended for removal and thus not included in the final list. Steroid dependency was removed from the final list because of the low ranking it received during the global ranking task of the first round of voting (12th place) as well as due to patient and physician feedback received during the second round of voting. The full survey used in the second round of voting is available in the ESM. The final descriptive framework generated from the results of the structured surveys included ten attributes, grouped into three domains (efficacy, complications/risk, and HRQoL; Table [2](#Tab2){ref-type="table"}).Fig. 2Frequencies of stated attributes dropped by patients. \*Used as a complementary source to confirm that all the relevant endpoints in clinical investigation had been identifiedTable 2Final list of attributesDomainAttribute name/descriptorEfficacyAbdominal painOther disease-related pain (anal pain, joint pain/stiffness or eye pain, etc.)Bowel urgency (when you feel the need for a bowel movement, you have to rush to the toilet to avoid an accident)Fatigue (an overwhelming sense of continuing tiredness, lack of energy or feeling exhausted that is not relieved by rest or sleep)Complications/riskRisk of cancer and serious infections within the next 10 years (excluding non-melanoma skin cancer)Risk of mild to moderate complications (mild/moderate complications means nausea, vomiting, headache, non-serious infections, lab abnormalities, skin reactions, and infusion reactions)Aesthetic complications related to treatment (hair loss, unintentional weight change, facial hair, acne, puffy face)Health-related quality of lifeEmotional statusSexual lifeSocial life and relationships (interpersonal interactions)

Discussion {#Sec10}
==========

This study reports the process and results of a three-step approach to understand the attributes that patients most highly value when making decisions about IBD treatment. To our knowledge, this research is the first study that defines a descriptive set of attributes based on input from patients with IBD. Our research could serve as a foundation for future quantitative studies that aim at defining the importance of these attributes when making treatment decisions for IBD; the attributes presented here should be adapted to the specific needs of the study. In order to proceed to quantitative research, levels should be assigned to the selected attributes and should be tested in a patient preferences study. Results from this type of study could also be valuable in directing the evolution of endpoints used in future IBD interventional trials.

This research highlights the ten most relevant attributes across domains of efficacy, complications/risk, and HRQoL that are most influential to a patient's decision regarding IBD treatment. The resulting practical descriptive framework will enable investigators to conduct further quantitative research to better understand the priorities of patients with IBD and to estimate the relative importance of each attribute/levels by means of discrete choice methods. When these levels of importance are clear, the quantification of how much more important one attribute may be compared to another can be communicated not only to other patients, but also to other stakeholders.

Of the attributes not deemed relevant by patients during the second round of online voting, we speculate that "functional performance in daily activities" was excluded from the final list because patients likely associate functional performance with symptom resolution. Interestingly, stool frequency was not considered as relevant for patients as bowel urgency (defined as the need to rush to the toilet to avoid an accident), and therefore was dropped from the list. The need to remain on steroids was also deprioritized (considering the gastroenterologist perspective); nevertheless, aesthetic complications (most of them related to prolonged steroid exposure) was kept as a relevant attribute, indicating that steroid dependency is still a matter of concern.

In a recent study that used an online iterative Delphi consensus process to develop an instrument to measure IBD-related disability, authors agreed to include ten items of high importance to both patients and physicians (abdominal pain, body image, education and work, emotions, energy, interpersonal interactions, joint pain, regulating defecation, sexual functions, and sleep) within the tool and are in agreement with the attributes identified in the current study presented here \[[@CR21]\]. The results of the current research are also consistent with previous studies that demonstrated that patients rate quality of life higher than gains in productivity \[[@CR16]\], and improvements in quality of life and symptom control are priority treatment objectives for IBD patients, with abdominal pain and bowel movement urgency being the most important symptoms \[[@CR15]\].

The present research has several limitations. When used for qualitative literature review, the PICOS framework has several limitations that can impact the quality of clinical evidence obtained under its guidance \[[@CR22]\]. Acknowledged limitations of the PICOS framework for qualitative evidence research include the fact that the framework does not accommodate terms relating to qualitative research. For example, the "Intervention" and "Comparison" components are not relevant for qualitative research, which traditionally does not utilize interventions and control groups. Additionally, combining the "Population" and "Intervention" components generally retrieves references to quantitative research. For this reason, it is possible that we were unable to capture and include all relevant publications. Another limitation of the literature review is that only previous health preference studies were included. By doing so, we may have missed concepts and themes from other types of studies that could have provided relevant attributes. The focus group meeting has inherent limitations that need to be acknowledged \[[@CR23]\]. Focus groups may be influenced by one or several group members dominating the discussion and articulating their opinions alone, thus, limiting the opinions of other participants. It is also possible that the research team and its facilitation of the discussion may have influenced the participants' responses, or that the patient voice may not exhibit the same weight as the physicians. Finally, the patient participants in this study may not convey the voice of all patients with IBD, but rather the experience limited to this small group. However, the structured rounds of voting were created to minimize the potential bias introduced by more dominant participants in the focus group meeting. The focus group and the online structured voting rounds may also be limited by the small number of participants. Thus, the generalizability of the interpretation and conclusions may be affected. Finally, the same attributes were defined for UC and CD, as all the attributes included were considered meaningful for patients with both diseases. We acknowledge that the relative importance of attributes differs across diseases and should be addressed in a quantitative study.

A key strength of this research was the use of multiple approaches to identify relevant and valuable attributes in the form of literature review, focus meetings comprised of both patient and physician participants, and structured online rounds of voting to provide a broad understanding of the attributes that may influence IBD treatment decision-making. Although the opinions of both patients and physicians were taken into consideration in this research, more consideration was given to patients' responses during prioritization of the attributes, resulting in elimination of some attributes from the final list. Prioritization of the patient perspective in this study is consistent with recent statements from the National Health Council for the development of patient-centred measures, including those for the assessment of patient preferences for treatment alternatives \[[@CR24]\]. An additional strength of this study is the broad regional representation and physicians' clinical practice patterns.

Conclusions {#Sec11}
===========

This research identified the ten most relevant attributes that influence patients when making treatment choices. The descriptive framework developed from this study provides a better understanding of real-world decision making for patients with IBD and should be considered by physicians and nurses when discussing treatment options with patients. The current research serves as the foundation for future studies that will evaluate the utility of these attributes within clinical practice.
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